title: In vitro effect of cyclophosphamide on the binding of radiopharmaceuticals (99mTcO4- and 99mTc-MDP) to blood elements.
abstract: Sodium pertechnetate (99mTcO4-) and many 99mTc-products are the radiopharmaceuticals most frequently used in nuclear medicine. Using an in vitro model, we evaluated the effect of cyclophosphamide on percent radioactivity of 99mTcO4- and methylenediphosphonic acid (99mTc-MDP) bound to isolated blood elements. Blood samples were incubated with the two radiopharmaceuticals, plasma and blood cells were separated and precipitated, and soluble and insoluble fractions were separated. To evaluate the effect of cyclophosphamide, blood was incubated with this drug 1 h prior to the addition of the radiopharmaceuticals. The fraction of 99mTcO4- radioactivity was slightly higher in plasma (61.2 to 53.8%) than in blood cells (38.8 to 46.2%) up to 6 h and cyclophosphamide did not interfere with this distribution. The amount of 99mTc-MDP radioactivity was higher in plasma (91.1 to 87.2%) than in blood cells (8.9 to 12.8%) up to 24 h and cyclophosphamide did not modify it. The binding of 99mTcO4- to the insoluble fraction of plasma (4.9 to 6.1%) was low and cyclophosphamide did not interfere with it up to 6 h, but a small blockade (9.8 to 4.8%) was observed at 24 h. From 3 h on, cyclophosphamide slightly inhibited 99mTcO4- binding to blood cells (23.1 to 16.6%) and increased it at 24 h (31.2 to 14.3%). Cyclophosphamide did not alter 99mTc-MDP binding to the insoluble fraction of blood cells and slightly decreased 99mTc-MDP binding to the insoluble fraction of plasma (29.8 to 23.6%) up to 6 h.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Centro de Pesquisa Básica, Instituto Nacional de Câncer, Rio de Janeiro, Brasil.
authors.forename: E
authors.initials: E
authors.lastname: Ripoll-Hamer
authors.forename: L C
authors.initials: LC
authors.lastname: Freitas
authors.forename: E F
authors.initials: EF
authors.lastname: De-Paula
authors.forename: L M
authors.initials: LM
authors.lastname: Fonseca
authors.forename: B
authors.initials: B
authors.lastname: Gutfilen
authors.forename: M
authors.initials: M
authors.lastname: Bernardo-Filho
mesh_terms: D000477:Alkylating Agents / Q000494:pharmacology*; D001769:Blood / Q000187:drug effects*; D001798:Blood Proteins / Q000187:drug effects / Q000378:metabolism*; D003520:Cyclophosphamide / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D013670:Sodium Pertechnetate Tc 99m / Q000378:metabolism*; D013669:Technetium Tc 99m Medronate / Q000378:metabolism*
chemical_list: D000477:Alkylating Agents; D001798:Blood Proteins; D003520:Cyclophosphamide; D013670:Sodium Pertechnetate Tc 99m; D013669:Technetium Tc 99m Medronate